HighTower Advisors LLC Has $2.56 Million Stock Holdings in Inari Medical, Inc. (NASDAQ:NARI)

HighTower Advisors LLC reduced its position in shares of Inari Medical, Inc. (NASDAQ:NARI) by 5.9% in the 3rd quarter, Holdings Channel reports. The firm owned 61,968 shares of the company’s stock after selling 3,901 shares during the period. HighTower Advisors LLC’s holdings in Inari Medical were worth $2,556,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NARI. Nisa Investment Advisors LLC raised its holdings in shares of Inari Medical by 83.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after buying an additional 435 shares in the last quarter. GAMMA Investing LLC grew its position in Inari Medical by 67.2% in the third quarter. GAMMA Investing LLC now owns 1,177 shares of the company’s stock valued at $49,000 after acquiring an additional 473 shares during the last quarter. KBC Group NV grew its position in Inari Medical by 39.0% in the third quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after acquiring an additional 498 shares during the last quarter. Benjamin F. Edwards & Company Inc. raised its stake in Inari Medical by 39.4% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after acquiring an additional 522 shares in the last quarter. Finally, Covestor Ltd lifted its holdings in shares of Inari Medical by 63.5% in the third quarter. Covestor Ltd now owns 2,384 shares of the company’s stock worth $99,000 after acquiring an additional 926 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently issued reports on NARI. Piper Sandler upped their price objective on shares of Inari Medical from $50.00 to $52.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 29th. Canaccord Genuity Group upped their price target on shares of Inari Medical from $71.00 to $74.00 and gave the stock a “buy” rating in a report on Tuesday, October 29th. Stifel Nicolaus assumed coverage on Inari Medical in a research note on Tuesday, September 17th. They issued a “hold” rating and a $50.00 price target for the company. Truist Financial boosted their price objective on Inari Medical from $46.00 to $50.00 and gave the stock a “hold” rating in a research report on Tuesday, October 29th. Finally, Robert W. Baird increased their target price on Inari Medical from $66.00 to $67.00 and gave the company an “outperform” rating in a research report on Tuesday, October 29th. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $58.89.

Inari Medical Price Performance

Shares of NARI stock opened at $55.59 on Friday. The stock has a market capitalization of $3.25 billion, a PE ratio of -41.18 and a beta of 0.97. The business’s 50 day simple moving average is $48.70 and its 200 day simple moving average is $47.98. Inari Medical, Inc. has a one year low of $36.73 and a one year high of $67.13.

Insider Transactions at Inari Medical

In related news, CEO Andrew Hykes sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the sale, the chief executive officer now owns 445,310 shares of the company’s stock, valued at $22,265,500. This trade represents a 0.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director William Hoffman sold 40,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $45.83, for a total value of $1,833,200.00. Following the completion of the transaction, the director now directly owns 643,296 shares in the company, valued at approximately $29,482,255.68. This trade represents a 5.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 183,000 shares of company stock worth $8,855,600. Company insiders own 10.60% of the company’s stock.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.